0
0
August 5, 2025 – In a breakthrough that could reshape pain management worldwide, researchers at Kyoto University have announced the discovery of ADRIANA, a novel analgesic designed to offer potent pain relief without the severe downsides linked to opioids such as morphine and OxyContin. This development comes amid the ongoing opioid crisis, which claimed over 80,000 lives in the United States from overdose in 2023 alone.
A Novel Mechanism for Pain Relief
While traditional opioids act on the brain’s opioid receptors—often leading to dangerous side effects like respiratory depression and dependency—ADRIANA works through a completely different biological pathway. Inspired by the body’s natural response to pain and danger, the research team studied how noradrenaline, a neurotransmitter released during intense stress, activates α2A-adrenoceptors to reduce pain. Prior approaches that mimicked this response risked cardiovascular instability due to broader receptor effects.
Through innovative compound screening and the use of the TGFα shedding assay, the Kyoto group identified a compound that selectively blocks α2B-adrenoceptors. This specific targeting appears to both increase noradrenaline levels and activate α2A-adrenoceptors, resulting in pain relief without triggering dangerous cardiovascular side effects.
Promising Results and Next Steps
ADRIANA’s safety and efficacy are supported by successful trials in mice and promising early-phase clinical studies. A Phase I trial in healthy volunteers and a Phase II trial in patients recovering from lung cancer surgery led to highly favorable results. Kyoto University and BTB Therapeutics, a university-affiliated biotech firm, are now preparing for a large-scale Phase II trial in the United States.
If successful, ADRIANA would become the first non-opioid analgesic developed in Japan and could dramatically expand the options available for treating severe and chronic pain.
Hope in the Battle Against the Opioid Crisis
Beyond offering relief to patients, ADRIANA could help to address the societal impact of opioid addiction. “If successfully commercialized, ADRIANA would offer a new pain management option that does not rely on opioids, contributing significantly to the reduction of opioid use in clinical settings,” said Professor Masatoshi Hagiwara, the project’s lead researcher at Kyoto University.
The research team is now working to broaden clinical testing to encompass a variety of pain types, with the goal of making ADRIANA accessible to patients around the world.
Disclaimer: This article is based on early-stage research results, and ADRIANA has not yet received approval for widespread clinical use. The outcomes described are preliminary, and efficacy or safety in larger populations is still under investigation. Patients should consult healthcare professionals before considering any new treatment. For more information, see the original publication: Hagiwara, Masatoshi, “Discovery and development of an oral analgesic targeting the α2B adrenoceptor,” Proceedings of the National Academy of Sciences (2025).
